Sarepta Therapeutics
Market cap $1.58B 107.2M shares (10-Q, Nov 2, 2026) × $14.77 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- Catalent clean room agreement corporate4Q 2026Catalent clean room agreement corporate, 4Q 2026, routine
- ELEVIDYS readout1Q 2027ELEVIDYS readout, 1Q 2027, major
- ELEVIDYS ENDEAVOR readout1Q 2027ELEVIDYS ENDEAVOR readout, 1Q 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (11 active programs)
golodirsen
VYONDYS 53casimersen
AMONDYS 45ELEVIDYS
delandistrogene moxeparvovec-rokl · delandistrogene moxeparvovec · SRP-9001bidridistrogene xeboparvovec
SRP-9003SRP-1001
SRP-1003
ATXN2 siRNA
MMP7 siRNA
HTT siRNA
SRP-1005
Technology platforms
AAVrh74
Adeno-associated virus vector platform using the AAVrh.74 serotype to deliver gene therapy transgenes to target muscle cells; used for Duchenne muscular dystrophy (ELEVIDYS/SRP-9001) and limb-girdle muscular dystrophy programs (SRP-9003). Platform technology designation previously granted by FDA in June 2025, subsequently revoked.
Targets: dystrophin, beta-sarcoglycan
αvβ6 integrin-targeted delivery platform
siRNA delivery platform utilizing αvβ6 integrin targeting for muscle diseases, including facioscapulohumeral muscular dystrophy type 1 (FSHD1) and myotonic dystrophy type 1 (DM1)
Targets: αvβ6 integrin
Discontinued (3)
- patidistrogene bexoparvovec — Limb-Girdle Muscular Dystrophy · suspended as part of Restructuring; FDA clinical hold placed following patient death
- SRP-6004 — Limb-Girdle Muscular Dystrophy · suspended as part of Restructuring; FDA clinical hold placed
- SRP-9005 — Limb-Girdle Muscular Dystrophy · suspended as part of Restructuring; FDA clinical hold placed
Capital (as filed)
- Cash
- $473M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $406M Sep 30, 2026
- Long-term investments
- $109M Sep 30, 2026
- Operating cash flow
- $60.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $999M cash per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (11)
- 2026-11-06 UPDATE: Sarepta Therapeutics (SRPT) - The Calendar Gets a Date ★ Distilled Pro
- 2026-08-06 UPDATE: Sarepta Therapeutics (SRPT) - The Clock Slips a Quarter 🔒 Paid
- 2026-07-28 UPDATE: Sarepta Therapeutics (SRPT) - The Chair Gets Filled 🔒 Paid
- 2026-06-30 UPDATE: Sarepta Therapeutics (SRPT) - The FDA Took the Meeting
- 2026-05-06 UPDATE: Sarepta Therapeutics (SRPT) - The Headline Beat That Wasn’t 🔒 Paid
- 2026-04-27 UPDATE: Sarepta Therapeutics (SRPT) - The 10-K Mea Culpa 🔒 Paid
- 2026-03-28 UPDATE: Sarepta Therapeutics (SRPT) - Unsheathing the Sword 🔒 Paid
- 2026-03-21 UPDATE: Sarepta Therapeutics (SRPT) - Fortifying the Shield and Unsheathing the Sword 🔒 Paid
- 2026-03-08 UPDATE: Sarepta Therapeutics (SRPT) - The Other Shoe Drops 🔒 Paid
- 2026-03-01 UPDATE: Sarepta (SRPT) - The Captain Bails Before the Storm? 🔒 Paid
- 2026-02-13 Sarepta Therapeutics (SRPT): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (11 calls)
Every verdict Biotech Distilled has published on Sarepta Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-13 Speculative buy speculative Sarepta Therapeutics (SRPT): Scientific Deep Dive for Lead and Pipeline Products ELEVIDYS has durable 3-year efficacy data and a $1.86B revenue floor; accumulate slowly ahead of the 2H 2026 Cohort 8 readout while managing AAV toxicity risk.
- 2026-03-01 Hold UPDATE: Sarepta (SRPT) - The Captain Bails Before the Storm? Abrupt CEO departure introduces acute execution risk; hold existing positions but keep powder dry until the 1,200-patient safety data at the MDA Congress in March.
- 2026-03-08 Hold UPDATE: Sarepta Therapeutics (SRPT) - The Other Shoe Drops The 10-K reveals $165M in AAV manufacturing write-offs and an $884M Arrowhead charge; maintain hold while watching Q1 siRNA data and the MDA Congress safety presentation.
- 2026-03-21 Hold UPDATE: Sarepta Therapeutics (SRPT) - Fortifying the Shield and Unsheathing the Sword PMO full-approval submissions and Cohort 8 enrollment initiation are stabilizing moves, but the $165M manufacturing write-off overhang warrants waiting to add until Q3/Q4 Cohort 8 liver toxicity data.
- 2026-03-28 Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - Unsheathing the Sword First clinical siRNA data validates the $883M Arrowhead investment; the thesis is de-risking with a cash-flowing PMO Shield, Cohort 8 wildcard, and newly validated siRNA platform making $19.97 an attractive speculative entry.
- 2026-04-27 Hold UPDATE: Sarepta Therapeutics (SRPT) - The 10-K Mea Culpa Three of four original buy assumptions broke (ESSENCE failed, platform designation revoked, LGMD on clinical hold); the free pipeline option is gone and the risk/reward has shifted to a binary-event hold pending Cohort 8.
- 2026-05-06 Hold UPDATE: Sarepta Therapeutics (SRPT) - The Headline Beat That Wasn't Q1 ELEVIDYS revenue collapsed 73% YoY to $102M; the headline GAAP profit is an accounting artifact, and the thesis is now a single-event hold on Cohort 8 data in late Q4 2026/Q1 2027.
- 2026-06-30 Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The FDA Took the Meeting FDA accepting the PMO sNDAs modestly de-risks the Shield, but the dominant variable remains Cohort 8 sirolimus data; at $17.97 the stock is closer to fair value for a binary-hold but not yet a compelling entry.
- 2026-07-28 Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The Chair Gets Filled Hiring development-focused CEO Severino retires the leadership-vacuum risk premium but cannot change Cohort 8 outcomes; the binary is still measured in sirolimus weeks and liver enzymes, not résumés.
- 2026-08-06 Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The Clock Slips a Quarter Cash stabilized with a $197M build and operating burn nearly zero, but Cohort 8 full enrollment slipped to year-end 2026 with 12-week data now formally in Q1 2027, extending the hold by a quarter.
- 2026-11-06 Speculative buy speculative UPDATE: Sarepta Therapeutics (SRPT) - The Calendar Gets a Date PMO PDUFA date set for Feb 28 2027 and cash near $1B are positives, but ELEVIDYS broke below the $400M annualized floor and the Catalent charge confirms AAV franchise shrinkage; the thesis now rests on the Q1 2027 MAD/PDUFA/Cohort 8 catalyst stack.
- Long call · opened Feb 13, 2026 at $17.79 · -17.0% vs XBI +18.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The Court also entered an amended scheduling order, with trial scheduled for June 14, 2027.”
matched to ELEVIDYS (ENDEAVOR Cohort 8) · readout other
-
-
-
“The Court also entered an amended scheduling order, with trial scheduled for June 14, 2027.”
matched to ELEVIDYS (ENDEAVOR Cohort 8) · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (29)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 5, 2026ReleaseSarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1→ BD updateQ3 2026 earnings land with the PMO sNDA PDUFA date finally disclosed (February 28, 2027), MAD data for SRP-1003 and SRP-1001 locked in for Q4 2026 with Phase 3 prep already underway, and the balance sheet growing to ~$999M — but a new $62M Catalent take-or-pay charge and a 7.5% session drop heading into the print keep the tension alive.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 26, 2026ReleaseSarepta Therapeutics to Present at Upcoming Investor Conferencesvia aggregator
- Oct 22, 2026ReleaseSarepta Therapeutics to Announce Third Quarter 2026 Financial Results
- Oct 14, 2026ReleaseSarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual MeetingBD extracted 1 program update from this document → SRPT pipeline
- Sep 30, 2026ReleaseSarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in OldeBD extracted 1 program update from this document → SRPT pipeline
- Sep 25, 2026ReleaseSarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
- Sep 24, 2026ReleaseSarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific MeetingBD extracted 3 program updates from this document → SRPT pipeline
- Sep 23, 20268-KCurrent report: material agreement
- Sep 8, 2026ReleaseSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
- Sep 8, 2026ReleaseSarepta Therapeutics anuncia a los destinatarios de Route 79, el Programa de Becas de Duchenne, para el año académico 2026-2027
- Aug 31, 2026ReleaseSarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conferencevia aggregator
- Aug 5, 2026ReleaseSarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate DevelopmentsBD extracted 2 program updates from this document → SRPT pipeline
- Aug 5, 20268-KCurrent report: results of operations · EX-99.1
- Aug 5, 202610-QQuarterly report
- Jul 27, 2026ReleaseSarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
- Jul 27, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- Jul 22, 2026ReleaseSarepta Therapeutics to Announce Second Quarter 2026 Financial Results
- Jun 30, 2026ReleaseSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
- Jun 4, 20268-KCurrent report: officer / director change, shareholder vote
- Jun 1, 2026ReleaseSarepta Therapeutics to Participate in Upcoming Investor Conferencesvia aggregator
- May 13, 2026ReleaseSarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
- May 6, 2026ReleaseSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
- May 6, 20268-KCurrent report: results of operations · EX-99.1
- May 6, 202610-QQuarterly report
- Apr 24, 2026DEFA14AProxy soliciting material
- Apr 24, 2026DEF 14AProxy statement
- Mar 2, 202610-KAnnual report
15 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- Nov 13, 202613F-HR13F-HR
- Nov 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 202613F-HR13F-HR
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 31, 2026SCHEDULE 13G/A13G amendment
- Jul 30, 2026SCHEDULE 13G/A13G amendment
- Jul 28, 2026S-8Employee plan registration
- Jun 4, 2026S-8Employee plan registration
- May 13, 202613F-HR13F-HR
- Apr 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 24, 2026ARSAnnual report to shareholders
- Mar 27, 2026SCHEDULE 13G/A13G amendment